Home › Companies › Alnylam Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Alnylam Pharmaceuticals, Inc.’s Form 8-K, filed 2026-05-27 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Alnylam Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Alnylam Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-27 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Stuart A. Arbuckle | 115,269,659 | 5,068,463 | 28,296 | -- | 5,450,286 | Majority: yes |
| Elect Director: Yvonne L. Greenstreet, M.D. | 119,787,307 | 513,049 | 66,062 | -- | 5,450,286 | Majority: yes |
| Elect Director: Elliott Sigal, M.D., Ph.D. | 107,495,421 | 12,844,836 | 26,161 | -- | 5,450,286 | Majority: yes |
| The terms of office of the following directors continued after the Annual Meeting: Dennis A. Ausiello, M.D. | 111,772,389 | 8,552,534 | 41,495 | -- | 5,450,286 | Majority: yes |
| Proposal 3: The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026. | 119,847,735 | 5,937,274 | 31,695 | -- | 0 | Majority: yes |
Source: Alnylam Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-05-27 — read the filing on EDGAR.
Each item below shows how the 716 asset managers that disclosed a Alnylam Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Alnylam Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-05-20.
Combines 8 wordings of this item as funds reported it.
96% fund support · no official result
The 675 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 27,117,380 | 0 | 0 | 0 | For |
| Capital Group | 23,523,321 | 0 | 0 | 0 | For |
| Vanguard | 15,947,302 | 46 | 0 | 0 | For |
| T. Rowe Price | 10,257,791 | 518,836 | 0 | 0 | For |
| BlackRock | 9,528,578 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 9,449,428 | 0 | 0 | 0 | For |
| Invesco | 3,478,355 | 1,344,033 | 0 | 0 | For |
| JPMorgan | 3,823,006 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,279,469 | 0 | 0 | 0 | For |
| American Century | 2,896,646 | 0 | 0 | 0 | For |
| State Street | 2,777,539 | 3,361 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,670,197 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Wellington | 1,852,421 | 0 | 0 | 0 | For |
| Charles Schwab | 1,386,350 | 0 | 0 | 0 | For |
| Federated Hermes | 1,160,860 | 4,088 | 0 | 0 | For |
| Clearbridge Investments, LLC | 1,113,021 | 0 | 0 | 0 | For |
| Jackson National | 1,019,309 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 871,986 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 809,469 | 0 | 0 | 0 | For |
| Northern Trust | 760,815 | 0 | 0 | 0 | For |
| Two Sigma | 696,784 | 0 | 0 | 0 | For |
| Voya | 640,521 | 0 | 0 | 0 | For |
Showing the 25 largest of 675 asset managers. See all 675 in the interactive database.
Meeting held 2026-05-20.
Combines 8 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Elliott Sigal, M.D., Ph.D.”): 107,495,421 for, 12,844,836 against, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 132,376,000 outstanding shares: 81% for, 10% against (91% of the company cast a for/against vote).
The 154 asset managers below cast 92% of the shares they voted on this item FOR (68,794,166 for, 5,761,800 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,186 | 103 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 4,184,185 | 0 | 0 | Against |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 408,600 | 610,709 | 0 | 0 | Against |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,643 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 944 | 332,986 | 0 | 0 | Against |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 193,366 | 38,126 | 0 | 0 | For |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 154 asset managers. See all 154 in the interactive database.
Meeting held 2026-05-20.
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Stuart A. Arbuckle”): 115,269,659 for, 5,068,463 against, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 132,376,000 outstanding shares: 87% for, 4% against (91% of the company cast a for/against vote).
The 154 asset managers below cast 94% of the shares they voted on this item FOR (70,280,737 for, 4,275,228 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,245 | 44 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 991,003 | 3,193,182 | 0 | 0 | Against |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 408,600 | 610,709 | 0 | 0 | Against |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,643 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,930 | 0 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 231,492 | 0 | 0 | 0 | For |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 154 asset managers. See all 154 in the interactive database.
Meeting held 2026-05-20.
Combines 7 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Yvonne L. Greenstreet, M.D.”): 119,787,307 for, 513,049 against, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 132,376,000 outstanding shares: 90% for, 0.4% against (91% of the company cast a for/against vote).
The 154 asset managers below cast 99.9% of the shares they voted on this item FOR (74,493,888 for, 62,075 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,284 | 3 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,184,185 | 0 | 0 | 0 | For |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 1,019,309 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,643 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,930 | 0 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 201,362 | 30,130 | 0 | 0 | For |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 154 asset managers. See all 154 in the interactive database.
Meeting held 2026-05-20.
Combines 6 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026.”): 119,847,735 for, 5,937,274 against, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 132,376,000 outstanding shares: 91% for, 4% against (95% of the company cast a for/against vote).
The 154 asset managers below cast 99.0% of the shares they voted on this item FOR (73,845,225 for, 710,740 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,088,432 | 659,857 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,184,185 | 0 | 0 | 0 | For |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 1,019,309 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,643 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,919 | 11 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 231,492 | 0 | 0 | 0 | For |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 154 asset managers. See all 154 in the interactive database.
Meeting held 2026-05-20.
86% fund support · no official result
The 24 asset managers below cast 86% of the shares they voted on this item FOR (397,631 for, 65,743 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Lincoln Financial | 69,471 | 0 | 0 | 0 | For |
| STOREBRAND ASSET MANAGEMENT AS | 64,851 | 0 | 0 | 0 | For |
| ANTIPODES PARTNERS Ltd | 59,320 | 0 | 0 | 0 | For |
| Wilshire Advisors LLC | 42,105 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 39,210 | 0 | 0 | 0 | For |
| Cardano Risk Management B.V. | 0 | 38,383 | 0 | 0 | Against |
| GROUPAMA ASSET MANAGMENT | 36,767 | 0 | 0 | 0 | For |
| Life Cycle Investment Partners Ltd | 33,820 | 0 | 0 | 0 | For |
| Empower | 21,622 | 0 | 0 | 0 | For |
| Vinva Investment Management Ltd | 17,984 | 0 | 0 | 0 | For |
| MIROVA | 0 | 14,014 | 0 | 0 | Against |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 13,346 | 0 | 0 | Against |
| Osmosis Investment Management UK Ltd | 3,183 | 0 | 0 | 0 | For |
| Metzler Asset Management GmbH | 2,730 | 0 | 0 | 0 | For |
| TD Waterhouse Canada Inc. | 2,041 | 0 | 0 | 0 | For |
| Plato Investment Management Ltd | 1,764 | 0 | 0 | 0 | For |
| Maj Invest Holding A/S | 1,203 | 0 | 0 | 0 | For |
| BlackRock | 1,083 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 0 | 0 | Not Voted |
| Qtron Investments LLC | 348 | 0 | 0 | 0 | For |
| Edgemoor Investment Advisors, Inc. | 100 | 0 | 0 | 0 | For |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma | 21 | 0 | 0 | 0 | For |
| UNIFIED SERIES TRUST | 5 | 0 | 0 | 0 | For |
| Cornerstone Investment Partners, LLC | 3 | 0 | 0 | 0 | For |
Meeting held 2026-05-20.
Combines 4 wordings of this item as funds reported it.
100% fund support · no official result
The 5 asset managers below cast 100% of the shares they voted on this item FOR (1,205,394 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Orbis Allan Gray Ltd | 1,134,001 | 0 | 0 | 0 | For |
| Fiera Capital Corp | 71,393 | 0 | 0 | 0 | For |
| National Philanthropic Trust | 0 | 0 | 0 | 0 | Take No Actio- |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 0 | -- |
| IPConcept (Luxemburg) S.A. | 0 | 0 | 0 | 0 | -- |
Meeting held 2025-05-08 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Proposal 4: The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers.”): 111,725,907 for, 6,909,706 against, per its Form 8-K filed 2025-05-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 132,376,000 outstanding shares: 84% for, 5% against (90% of the company cast a for/against vote).
The 3 asset managers below cast 87% of the shares they voted on this item FOR (10,337 for, 1,541 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Investment Management Corp of Ontario | 10,107 | 0 | 0 | 0 | For |
| OSSIAM | 0 | 1,541 | 0 | 0 | Against |
| OSBORNE PARTNERS CAPITAL MANAGEMENT, LLC | 230 | 0 | 0 | 0 | For |
Meeting held 2026-05-20.
100% fund support · no official result
The 3 asset managers below cast 100% of the shares they voted on this item FOR (921 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Modern Wealth Management, LLC | 460 | 0 | 0 | 0 | For |
| Tandem Financial, LLC | 460 | 0 | 0 | 0 | For |
| Dash Acquisitions Inc. | 1 | 0 | 0 | 0 | For |
Reported under meeting date 2026-03-25; no official results on file for that date.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (67,493 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SCHRODER INVESTMENT MANAGEMENT GROUP | 64,713 | 0 | 0 | 0 | For |
| Robertson Stephens Wealth Management, LLC | 2,780 | 0 | 0 | 0 | For |
Meeting held 2026-05-20.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (1 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| LEAVELL INVESTMENT MANAGEMENT, INC. | 0 | 0 | 50 | 0 | Abstain |
| Baker Avenue Asset Management, LP | 1 | 0 | 0 | 0 | For |
Meeting held 2026-05-20.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (62,094 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Lincoln Financial | 62,094 | 0 | 0 | 0 | For |
| FAIRVIEW CAPITAL INVESTMENT MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
Meeting held 2026-05-20.
42% fund support · no official result
The 2 asset managers below cast 42% of the shares they voted on this item FOR (121 for, 170 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Genus Capital Management Inc. | 0 | 170 | 0 | 0 | Against |
| Empower | 121 | 0 | 0 | 0 | For |
Ranked by the number of Alnylam Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 132,376,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 20.49% |
| 2 | Capital Group | 17.77% |
| 3 | Vanguard | 12.05% |
| 4 | T. Rowe Price | 8.14% |
| 5 | BlackRock | 7.20% |
| 6 | Capital Research Global Investors | 7.14% |
| 7 | Invesco | 3.64% |
| 8 | JPMorgan | 2.89% |
| 9 | AMCAP FUND | 2.83% |
| 10 | Dodge & Cox | 2.48% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 11.01% | 13F |
| Capital World Investors | 8.25% | 13G |
| BlackRock | 7.89% | 13F |
| Capital Research Global Investors | 7.15% | 13G |
| JPMorgan Chase | 4.78% | 13F |
| State Street | 2.51% | 13F |
| Two Sigma | 1.51% | 13F |
| Wellington Management | 1.46% | 13F |
| D.E. Shaw | 1.11% | 13F |
| T. Rowe Price | 1.08% | 13F |
Percentages above are of 132,376,000 shares outstanding, as reported by Alnylam Pharmaceuticals, Inc. on its Form 10-K dated 2025-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Alnylam Pharmaceuticals, Inc.’s 10-K dated 2025-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Alnylam Pharmaceuticals, Inc.'s shareholder meeting held 2026-05-20, in the 2025-2026 proxy season, 716 asset managers reported how they voted in their SEC Form N-PX filings, covering 4,703 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Alnylam Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive… — the reporting funds cast 96% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.
Alnylam Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).